Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

DANVILLE, Pa., RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 25, 2017 /PRNewswire/ -- In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (NYSE: LLY), today announced a major collaboration to develop a risk-prediction model for three critical health outcomes commonly associated with type 2 diabetes that have long-term impact and cost-of-care implications: cardiovascular death, kidney failure and hospitalization for heart failure.

https://investor.lilly.com/releasedetail.cfm?ReleaseID=1041519

Lilly to Participate in UBS Global Healthcare Conference (NYSE:LLY)

Lilly to Participate in UBS Global Healthcare Conference (NYSE:LLY)

New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis (NYSE:LLY)

New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis (NYSE:LLY)

Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®' (NYSE:LLY)

Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®' (NYSE:LLY)

Lilly Completes Acquisition of CoLucid Pharmaceuticals (NYSE:LLY)

Lilly Completes Acquisition of CoLucid Pharmaceuticals (NYSE:LLY)

Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting (NYSE:LLY)

INDIANAPOLIS, Feb. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz^® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75^th annual meeting of the American Academy of Dermatology (AAD), which will take place March 3-7, 2017, in Orlando, Fla.



Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting (NYSE:LLY)